Cellcentric Ltd

CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda

Older News

CAMBRIDGE, England, February 25, 2010 - From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy